
    
      It is an open, randomized, crossover 2x2, single dose, with the administration of medicine
      with 28 healthy volunteers, adults aged 18-50 years, of both genders (14 males and 14
      females). Of the 28 volunteers planned in the study protocol to start, gave up one (woman)
      before the start of Phase I. So the study was initiated and completed with the participation
      of 27 volunteers. The volunteers were in hospital for a period of approximately 36 hours in
      each stage.
    
  